Your browser doesn't support javascript.
loading
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
Rhyasen, Garrett W; Yao, Yi; Zhang, Jingwen; Dulak, Austin; Castriotta, Lillian; Jacques, Kelly; Zhao, Wei; Gharahdaghi, Farzin; Hattersley, Maureen M; Lyne, Paul D; Clark, Edwin; Zinda, Michael; Fawell, Stephen E; Mills, Gordon B; Chen, Huawei.
Affiliation
  • Rhyasen GW; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Yao Y; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Zhang J; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Dulak A; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Castriotta L; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Jacques K; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Zhao W; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
  • Gharahdaghi F; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Hattersley MM; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Lyne PD; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Clark E; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Zinda M; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Fawell SE; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
  • Mills GB; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
  • Chen H; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Boston, Massachusetts, United States of America.
PLoS One ; 13(7): e0200826, 2018.
Article in En | MEDLINE | ID: mdl-30036377
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Piperazines / Transcription Factors / Nuclear Proteins / Gene Expression Regulation, Neoplastic / Heterocyclic Compounds, 2-Ring / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2018 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Piperazines / Transcription Factors / Nuclear Proteins / Gene Expression Regulation, Neoplastic / Heterocyclic Compounds, 2-Ring / Antineoplastic Agents Type of study: Diagnostic_studies / Prognostic_studies Limits: Animals / Female / Humans Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2018 Document type: Article Affiliation country: United States Country of publication: United States